Q19-20: Disease Relapse or Progression

*Combined Follow-Up
In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, these questions do not apply and are disabled.

*Disease Relapse or Progression
The disease relapse or progression questions are applicable for malignant diseases when disease specific forms are not present (TED level reporting).
Relapse criteria vary by disease and are outlined in the CIBMTR Forms Instructions Manual. Refer to the appropriate disease response criteria section of the Forms Instructions Manual and review the criteria to report relapse.

Questions 19-20: Was a disease relapse or progression detected?

Disease relapse or progression can be documented by a variety of methods including molecular, flow cytometry, cytogenetic/fluorescent in situ hybridization (FISH), radiographic or hematological / clinical. The intent is to capture any new relapse or progression event that occurred in the reporting period, not just the initial relapse or progression.

Report Yes if any new disease relapse or progression was detected by any one of the methods in the current reporting period and report the first date of the relapse or progression detected in this reporting period.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.